Meta Analysis Confirms Weight Loss Benefit of Semaglutide, Flags Evidence Gaps

A systematic review and meta analysis published in the Journal of Diabetes and Metabolic Disorders pooled data from 10 randomized controlled trials totaling 7,131 adults with overweight or obesity who did not have diabetes, comparing semaglutide to placebo, according to the PubMed listing.

Across the trials, semaglutide produced an average body weight reduction of about 12.3 percent compared to placebo, along with meaningful drops in BMI and waist circumference. Participants on semaglutide were also more likely to reach weight loss thresholds of 5 percent or more.

The safety picture was more mixed. People taking semaglutide reported more total adverse events than those on placebo, 90 percent versus 85 percent, and discontinued treatment due to side effects at roughly double the rate. The analysis found no clear difference in serious adverse events, though the data could not rule out a meaningful increase in risk.

The authors rated the certainty of evidence as low for weight related outcomes and very low for waist circumference, citing substantial variation between trials in dose, duration, and patient populations. They concluded that semaglutide shows a clinically meaningful effect during the treatment period studied, but cautioned that the exact magnitude of benefit should be interpreted carefully given these limitations.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.